Core Insights - Mineralys Therapeutics, Inc. is a clinical-stage biopharmaceutical company focused on developing treatments for hypertension, chronic kidney disease (CKD), obstructive sleep apnea (OSA), and other diseases related to dysregulated aldosterone [1][3] - The company will host a conference call featuring Dr. Luke Laffin from the Cleveland Clinic to discuss results from the Advance-HTN and Launch-HTN clinical trials, highlighting the unmet medical needs in uncontrolled and resistant hypertension [1] Company Overview - Mineralys Therapeutics is based in Radnor, Pennsylvania, and was founded by Catalys Pacific [3] - The company's lead product candidate, lorundrostat, is an orally administered, highly selective aldosterone synthase inhibitor aimed at treating cardiorenal conditions influenced by dysregulated aldosterone [3] Upcoming Events - A conference call and webinar will take place on April 1st at 8:00 a.m. ET, where a live webcast will also be available on the company's Investor Relations page [2]